JP7792333B2 - Ｂｃｍａおよびｃｄ３に対する抗体を用いる処置方法 - Google Patents

Ｂｃｍａおよびｃｄ３に対する抗体を用いる処置方法

Info

Publication number
JP7792333B2
JP7792333B2 JP2022525788A JP2022525788A JP7792333B2 JP 7792333 B2 JP7792333 B2 JP 7792333B2 JP 2022525788 A JP2022525788 A JP 2022525788A JP 2022525788 A JP2022525788 A JP 2022525788A JP 7792333 B2 JP7792333 B2 JP 7792333B2
Authority
JP
Japan
Prior art keywords
antibody
dose
seq
bispecific
bcma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553822A5 (enExample
JP2022553822A (ja
Inventor
バージェス，マイケル
ヒージ，クリステン
ダッタ，カウシク
ボス，アイザック
ディエム ヴー，ミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2022553822A publication Critical patent/JP2022553822A/ja
Publication of JP2022553822A5 publication Critical patent/JP2022553822A5/ja
Application granted granted Critical
Publication of JP7792333B2 publication Critical patent/JP7792333B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022525788A 2019-11-05 2020-11-04 Ｂｃｍａおよびｃｄ３に対する抗体を用いる処置方法 Active JP7792333B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19207293 2019-11-05
EP19207293.2 2019-11-05
EP20179573 2020-06-11
EP20179573.9 2020-06-11
PCT/US2020/058939 WO2021092056A1 (en) 2019-11-05 2020-11-04 Methods of treatment with antibodies against bcma and cd3

Publications (3)

Publication Number Publication Date
JP2022553822A JP2022553822A (ja) 2022-12-26
JP2022553822A5 JP2022553822A5 (enExample) 2023-11-13
JP7792333B2 true JP7792333B2 (ja) 2025-12-25

Family

ID=75849140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525788A Active JP7792333B2 (ja) 2019-11-05 2020-11-04 Ｂｃｍａおよびｃｄ３に対する抗体を用いる処置方法

Country Status (11)

Country Link
US (1) US20230057602A1 (enExample)
EP (1) EP4054725A4 (enExample)
JP (1) JP7792333B2 (enExample)
KR (1) KR20220093141A (enExample)
CN (1) CN115279459A (enExample)
AU (1) AU2020379757A1 (enExample)
BR (1) BR112022008516A2 (enExample)
CA (1) CA3160137A1 (enExample)
IL (1) IL292704A (enExample)
MX (1) MX2022005292A (enExample)
WO (1) WO2021092056A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
SI3819007T1 (sl) 2019-11-11 2024-10-30 Amgen Inc. Režim odmerjanja sredstev proti BCMA
CN119569887A (zh) * 2021-06-24 2025-03-07 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
WO2025042742A1 (en) * 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025117764A1 (en) * 2023-12-01 2025-06-05 Teneoone, Inc. Methods for the treatment of multiple myeloma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018083204A1 (en) 2016-11-02 2018-05-11 Engmab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738568C (en) * 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
AU2016302881B2 (en) * 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018083204A1 (en) 2016-11-02 2018-05-11 Engmab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Best Pract Res Clin Haematol，2017年，Vol. 30，pp. 336-340
Lancet Oncol，2015年，Vol. 16，pp. 57-66
Mol Cancer Ther，2019年08月21日，Vol. 18, No. 11，pp. 2008-2020

Also Published As

Publication number Publication date
AU2020379757A1 (en) 2022-05-26
US20230057602A1 (en) 2023-02-23
WO2021092056A1 (en) 2021-05-14
EP4054725A1 (en) 2022-09-14
KR20220093141A (ko) 2022-07-05
CA3160137A1 (en) 2021-05-14
CN115279459A (zh) 2022-11-01
MX2022005292A (es) 2022-08-10
EP4054725A4 (en) 2024-01-10
JP2022553822A (ja) 2022-12-26
IL292704A (en) 2022-07-01
BR112022008516A2 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
US20230057602A1 (en) Methods of treatment with antibodies against bcma and cd3
TWI788327B (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
CN110167964B (zh) 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
KR102364383B1 (ko) 삼중-특이적 결합 분자 및 그것의 사용 방법
EP3658585A1 (en) Anti-ctla-4 antibodies and uses thereof
TWI847977B (zh) 變體ｃｄ３-結合結構域及其在用於治療疾病的組合療法中的用途
JP7783183B2 (ja) 自己免疫障害における抗ｂｃｍａ治療
US11987636B2 (en) Dosing of a bispecific antibody that binds CD20 and CD3
WO2021092060A1 (en) Methods of treatment
TW202104263A (zh) 雙特異性CD123xCD3雙抗體在血液系統惡性腫瘤治療中的給藥方案
US20210246194A1 (en) Optimized gp41-Binding Molecules and Uses Thereof
IL254335B (en) Isolated peptides derived from the dimerization regions of b7
US20230172923A1 (en) Methods of treating cytokine-related adverse events
EA049790B1 (ru) Способы лечения антителами к bcma и cd3
HK40083315A (en) Methods of treatment with antibodies against bcma and cd3
WO2025042742A1 (en) Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
EA050324B1 (ru) Терапия антителами против bcma при аутоиммунных расстройствах

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231102

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251215

R150 Certificate of patent or registration of utility model

Ref document number: 7792333

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150